In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (09/2008)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bone Building Start-Ups," features profiles of OsteoCorp, OsteoGeneX, Pradama, and Therosteon. Plus these Start-Ups Across Health Care: Aileron Therapeutics, Cohera Medical, CoLucid Pharmaceuticlas and Endogun Medical Systems.

You may also be interested in...

Cohera Medical Inc.

The lead product from Cohera Medical platform technology is a sprayable adhesive strong enough to hold tissue layers together following surgery. TissuGlu is an absorbable, urethane adhesive that is non-toxic for use inside the body. The initial indication will be plastic surgery, with an emphasis on abdominoplasty (tummy tuck). For such a procedure, the product is sprayed in between two flaps of tissue for reattachment, thus preventing fluid buildup that would otherwise occur between unattached layers of tissue and require cumbersome post-surgical drains with their associated complications.

Endogun Medical Systems Ltd.

Treating pelvic organ prolapse or stress urinary incontinence usually involves a multiple-incision approach and blind needle passage, which may cause pelvic organ damage. In contrast, the EndoFast Reliant system from Endogun Medical Systems fastens mesh to soft tissue for pelvic floor repair by inserting a fixation device through a single, small vaginal incision. The device may enable the treatment of both disorders within a single surgery.

Pradama Inc.

University of Louisville spin-out Pradama is developing bone-targeting technology that it says will precisely deliver estrogen drugs to promote bone growth without the side effects of other estrogen receptor modulators. Preclinical tests on its lead product for osteoporosis will begin in the first quarter of 2009.

Related Content

Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts